208 related articles for article (PubMed ID: 32384505)
21. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.
Kee KM; Wang JH; Hung CH; Chen CH; Lee CM; Lu SN
Dig Dis Sci; 2013 Feb; 58(2):556-61. PubMed ID: 23001404
[TBL] [Abstract][Full Text] [Related]
22. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
23. Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.
Jun BG; Park EJ; Lee WC; Jang JY; Jeong SW; Kim YD; Cheon GJ; Cho YS; Lee SH; Kim HS; Lee YN; Kim SG; Kim YS; Kim BS
Korean J Intern Med; 2019 Sep; 34(5):989-997. PubMed ID: 29529840
[TBL] [Abstract][Full Text] [Related]
24. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
[TBL] [Abstract][Full Text] [Related]
25. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
26. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience.
Tsai MC; Lin CY; Hung CH; Lu SN; Tung SY; Chien RN; Lin CL; Wang JH; Chien-Hung C; Chang KC; Hu TH; Sheen IS
J Viral Hepat; 2019 Dec; 26(12):1404-1412. PubMed ID: 31433885
[TBL] [Abstract][Full Text] [Related]
27. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
28. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
[TBL] [Abstract][Full Text] [Related]
29. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
30. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
Hermos JA; Quach L; Gagnon DR; Weber HC; Altincatal A; Cho K; Lawler EV; Grotzinger KM
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):480-8. PubMed ID: 24677630
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
Chen YC; Li CH; Ko PH; Lee CC; Syu RJ; Tseng CW; Tseng KC
PLoS One; 2021; 16(8):e0256505. PubMed ID: 34437608
[TBL] [Abstract][Full Text] [Related]
32. Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response.
Pal V; Ancha N; Mann J; Modi AA
Can J Gastroenterol Hepatol; 2020; 2020():8815829. PubMed ID: 32802821
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
35. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection.
Nakajima T; Karino Y; Hige S; Suii H; Tatsumi R; Yamaguchi M; Arakawa T; Kuwata Y; Toyota J
Ann Hepatol; 2022; 27(1):100566. PubMed ID: 34688887
[TBL] [Abstract][Full Text] [Related]
36. Impact of Helicobacter pylori eradication on refractory thrombocytopenia in patients with chronic HCV awaiting antiviral therapy.
Hanafy AS; El Hawary AT; Hamed EF; Hassaneen AM
Eur J Clin Microbiol Infect Dis; 2016 Jul; 35(7):1171-6. PubMed ID: 27180243
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
38. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
[TBL] [Abstract][Full Text] [Related]
40. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]